TY - JOUR
T1 - Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer
T2 - Does the current quality of evidence justify definitive conclusions?
AU - Wettstein, Marian S.
AU - Rooprai, Jasjit K.
AU - Pazhepurackel, Clinsy
AU - Wallis, Christopher J.D.
AU - Klaassen, Zachary
AU - Uleryk, Elizabeth M.
AU - Hermanns, Thomas
AU - Fleshner, Neil E.
AU - Zlotta, Alexandre R.
AU - Kulkarni, Girish S.
N1 - Publisher Copyright:
© 2019 Wettstein et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2019/4
Y1 - 2019/4
N2 - Objectives To systematically review and meta-analyze the current literature in a methodologically rigorous and transparent manner for quantitative evidence on survival outcomes among patients diagnosed with muscle-invasive bladder cancer that were treated by either trimodal therapy or radical cystectomy. Materials and methods MEDLINE, EMBASE, CENTRAL were systematically searched for comparative observational studies reporting disease-specific survival and/or overall survival on adult patients diagnosed with localized muscle-invasive bladder cancer that were exposed to either trimodal therapy or radical cystectomy. Studies qualified for meta-analysis (random effects model) if they were not at critical risk of bias (RoB). Results The literature search identified 12 eligible studies. Three (all rated as “moderate RoB”) out of 6 studies reporting on disease-specific survival qualified for quantitative analysis and yielded a pooled hazard ratio (trimodal therapy versus radical cystectomy) of 1.39 (95% confidence interval: 1.03–1.88). Four (mainly rated as “serious RoB”) out of 12 studies were included in the meta-analysis of overall survival and estimated a hazard ratio of 1.39 (1.20–1.59). Conclusion Pooled results were significant in favor of radical cystectomy. The conclusion is mainly driven by large population-based studies that are at high RoB. Hence, the certainty of these treatment estimates can be considered very low and further research will likely have an important impact on these estimates. At present, the ultimate decision between trimodal therapy and radical cystectomy should be left to the patient based on individual preferences and on the recommendation of a multidisciplinary provider team experienced with both approaches.
AB - Objectives To systematically review and meta-analyze the current literature in a methodologically rigorous and transparent manner for quantitative evidence on survival outcomes among patients diagnosed with muscle-invasive bladder cancer that were treated by either trimodal therapy or radical cystectomy. Materials and methods MEDLINE, EMBASE, CENTRAL were systematically searched for comparative observational studies reporting disease-specific survival and/or overall survival on adult patients diagnosed with localized muscle-invasive bladder cancer that were exposed to either trimodal therapy or radical cystectomy. Studies qualified for meta-analysis (random effects model) if they were not at critical risk of bias (RoB). Results The literature search identified 12 eligible studies. Three (all rated as “moderate RoB”) out of 6 studies reporting on disease-specific survival qualified for quantitative analysis and yielded a pooled hazard ratio (trimodal therapy versus radical cystectomy) of 1.39 (95% confidence interval: 1.03–1.88). Four (mainly rated as “serious RoB”) out of 12 studies were included in the meta-analysis of overall survival and estimated a hazard ratio of 1.39 (1.20–1.59). Conclusion Pooled results were significant in favor of radical cystectomy. The conclusion is mainly driven by large population-based studies that are at high RoB. Hence, the certainty of these treatment estimates can be considered very low and further research will likely have an important impact on these estimates. At present, the ultimate decision between trimodal therapy and radical cystectomy should be left to the patient based on individual preferences and on the recommendation of a multidisciplinary provider team experienced with both approaches.
UR - http://www.scopus.com/inward/record.url?scp=85065329556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065329556&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0216255
DO - 10.1371/journal.pone.0216255
M3 - Review article
C2 - 31034504
AN - SCOPUS:85065329556
SN - 1932-6203
VL - 14
JO - PloS one
JF - PloS one
IS - 4
M1 - e0216255
ER -